Literature DB >> 20437155

Protection against Helicobacter pylori infection by a trivalent fusion vaccine based on a fragment of urease B-UreB414.

Li Wang1, Xiao-Fei Liu, Shi Yun, Xiao-Peng Yuan, Xu-Hu Mao, Chao Wu, Wei-Jun Zhang, Kai-Yun Liu, Gang Guo, Dong-Shui Lu, Wen-De Tong, Ai-Dong Wen, Quan-Ming Zou.   

Abstract

A multivalent fusion vaccine is a promising option for protection against Helicobacter pylori infection. In this study, UreB414 was identified as an antigenic fragment of urease B subunit (UreB) and it induced an antibody inhibiting urease activity. Immunization with UreB414 partially protected mice from H. pylori infection. Furthermore, a trivalent fusion vaccine was constructed by genetically linking heat shock protein A (HspA), H. pylori adhesin A (HpaA), and UreB414, resulting in recombinant HspA-HpaA-UreB414 (rHHU). Its protective effect against H. pylori infection was tested in BALB/c mice. Oral administration of rHHU significantly protected mice from H. pylori infection, which was associated with H. pylori-specific antibody production and Th1/Th2-type immune responses. The results show that a trivalent fusion vaccine efficiently combats H. pylori infection, and that an antigenic fragment of the protein can be used instead of the whole protein to construct a multivalent vaccine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20437155     DOI: 10.1007/s12275-009-0233-4

Source DB:  PubMed          Journal:  J Microbiol        ISSN: 1225-8873            Impact factor:   3.422


  19 in total

1.  Essential role of urease in pathogenesis of gastritis induced by Helicobacter pylori in gnotobiotic piglets.

Authors:  K A Eaton; C L Brooks; D R Morgan; S Krakowka
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

2.  Supramolecular assembly and acid resistance of Helicobacter pylori urease.

Authors:  N C Ha; S T Oh; J Y Sung; K A Cha; M H Lee; B H Oh
Journal:  Nat Struct Biol       Date:  2001-06

3.  HpaA is essential for Helicobacter pylori colonization in mice.

Authors:  Elisabet Carlsohn; Johanna Nyström; Ingrid Bölin; Carol L Nilsson; Ann-Mari Svennerholm
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

4.  Oral immunization with HpaA affords therapeutic protective immunity against H. pylori that is reflected by specific mucosal immune responses.

Authors:  Johanna Nyström; Ann-Mari Svennerholm
Journal:  Vaccine       Date:  2006-12-26       Impact factor: 3.641

5.  Vaccine against Helicobacter pylori: fact or fiction?

Authors:  P Michetti
Journal:  Gut       Date:  1997-12       Impact factor: 23.059

6.  The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice.

Authors:  R L Ferrero; J M Thiberge; I Kansau; N Wuscher; M Huerre; A Labigne
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-03       Impact factor: 11.205

7.  Therapeutic vaccination against Helicobacter pylori in the beagle dog experimental model: safety, immunogenicity, and efficacy.

Authors:  Giacomo Rossi; Paolo Ruggiero; Samuele Peppoloni; Laura Pancotto; Damiano Fortuna; Laura Lauretti; Gianfranco Volpini; Silvia Mancianti; Michele Corazza; Ennio Taccini; Francesco Di Pisa; Rino Rappuoli; Giuseppe Del Giudice
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

Review 8.  Carcinogenesis of Helicobacter pylori.

Authors:  Pelayo Correa; Jeanmarie Houghton
Journal:  Gastroenterology       Date:  2007-08       Impact factor: 22.682

9.  Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant.

Authors:  M Marchetti; M Rossi; V Giannelli; M M Giuliani; M Pizza; S Censini; A Covacci; P Massari; C Pagliaccia; R Manetti; J L Telford; G Douce; G Dougan; R Rappuoli; P Ghiara
Journal:  Vaccine       Date:  1998-01       Impact factor: 3.641

10.  Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses.

Authors:  T H Ermak; P J Giannasca; R Nichols; G A Myers; J Nedrud; R Weltzin; C K Lee; H Kleanthous; T P Monath
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

View more
  5 in total

Review 1.  Helicobacter pylori in gastric malignancies.

Authors:  Abhishek Bhandari; Sheila E Crowe
Journal:  Curr Gastroenterol Rep       Date:  2012-12

2.  A recombinant chimeric protein containing B chains of ricin and abrin is an effective vaccine candidate.

Authors:  Junhong Wang; Shan Gao; Tao Zhang; Lin Kang; Wuchun Cao; Na Xu; Wensen Liu; Jinglin Wang
Journal:  Hum Vaccin Immunother       Date:  2014-02-07       Impact factor: 3.452

Review 3.  Exploring alternative treatments for Helicobacter pylori infection.

Authors:  Guadalupe Ayala; Wendy Itzel Escobedo-Hinojosa; Carlos Felipe de la Cruz-Herrera; Irma Romero
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

4.  Mimotopes selected with a neutralizing antibody against urease B from Helicobacter pylori induce enzyme inhibitory antibodies in mice upon vaccination.

Authors:  Yan Li; Yunshan Ning; Yundan Wang; Dandan Peng; Yaodong Jiang; Lili Zhang; Min Long; Jun Luo; Ming Li
Journal:  BMC Biotechnol       Date:  2010-11-30       Impact factor: 2.563

5.  Live Attenuated Measles Virus Vaccine Expressing Helicobacter pylori Heat Shock Protein A.

Authors:  Ianko D Iankov; Cheyne Kurokawa; Kimberly Viker; Steven I Robinson; Arun Ammayappan; Eleni Panagioti; Mark J Federspiel; Evanthia Galanis
Journal:  Mol Ther Oncolytics       Date:  2020-09-23       Impact factor: 7.200

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.